What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the KEYNOTE-868 trial indicates that pembrolizumab combined with carboplatin and paclitaxel significantly improves progression-free survival compared to carboplatin and paclitaxel alone. However, the overall survival benefit is less certain due to ongoing trials and limited follow-up data. This moderate benefit over current care justifies an ‘A’ rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for pembrolizumab with carboplatin and paclitaxel fall within NICE’s acceptable range for NHS resources, indicating a clear cost-effective profile under common thresholds. This supports a rating of A+.
Is there quality-of-life evidence payers weigh? — Quality of life
While health-related quality-of-life data was collected, it was not done using the EQ-5D, and the utility values derived from other studies may not fully represent the pMMR population. The committee expressed concerns about the generalizability of the utility values, leading to a rating of B++.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The treatment has a very good safety profile, with mostly mild to moderate adverse events reported. Serious adverse events are rare, supporting a rating of A+.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against the appropriate standard of care, which is platinum-based chemotherapy. This supports a rating of A for comparator selection.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is broadly representative of the intended patient population, with subgroup analyses for dMMR and pMMR cancers. This supports a rating of A.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment can be integrated into existing care pathways with minor adjustments, such as additional monitoring, supporting a rating of A+.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource use estimates are manageable and aligned with clinical practice, indicating a notable but justifiable cost burden, which supports a rating of A.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a robust Phase 3 trial design, although there are some concerns regarding the follow-up duration and generalizability. This supports a rating of A.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding long-term outcomes, the treatment addresses a significant unmet need in the population, supporting a rating of A.
